Torrent pharma, a leading drugmaker said in the exchange filing on Friday that the company Recommended to the members to obtain enabling approval for issuance of Equity Shares including Convertible Bonds / Debentures through Qualified Institutional Placement (QIP) and or any other modes for an amount not exceeding ₹ 5,000 crores in the upcoming Annual General Meeting of the Company.
Financial results update of Torrent pharma (Q4-FY24)
| Consolidated net profit | 449 crore (up 57% YOY) |
| Revenue | 2745 crore (up 10% YOY) |
| EBITDA | 883 crore (up 21% YOY) |
| Dividend | Rs 6 per equity share |
Some important numbers about Torrent pharma you need to know
| CMP | 2613 (-2.98% from previous day: 23rd May 2024) |
| 52 Week High/Low | 2,783 / 1,690 |
| Stock PE | 55.5 |
| ROE | 24.4% |
| ROCE | 23.3% |
| Debt to Equity ratio | 0.59 |
| Promoter holding/ Pledge percentage | 71.25% / 0.0% |
For education purpose only. The views are personal. The investments discussed or recommended in the market analysis, research reports, etc. may not be suitable for all investors. Investors must make their own investment decisions based on their specific investment objectives and financial position and only after consulting such independent advisors as may be necessary. We are not a registered financial advisor or research analyst.